113 related articles for article (PubMed ID: 10454000)
1. Platelet-activating factor plays a role in the mechanism of major histocompatibility complex in T lymphocytes.
Nikbakht-Sangari M; Qayumi AK; Keown P; Duronio V; Horley K
Immunol Invest; 1999 Jul; 28(4):223-33. PubMed ID: 10454000
[TBL] [Abstract][Full Text] [Related]
2. The role of inflammatory mediators in the mechanism of the host immune response induced by ischemia-reperfusion injury.
Nikbakht-Sangari M; Qayumi AK; Keown PA
Immunol Invest; 2000 Feb; 29(1):13-26. PubMed ID: 10709843
[TBL] [Abstract][Full Text] [Related]
3. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees.
Kuipers B; van der Poll T; Levi M; van Deventer SJ; ten Cate H; Imai Y; Hack CE; ten Cate JW
J Immunol; 1994 Mar; 152(5):2438-46. PubMed ID: 8133055
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation.
Kawamura M; Terashita Z; Imura Y; Shino A; Nishikawa K
Thromb Res; 1993 May; 70(4):281-93. PubMed ID: 8332959
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of TCV-309--a potent PAF antagonist.
Terashita Z; Takatani M; Nishikawa K
J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
7. Platelet-activating factor antagonist (TCV-309) attenuates the priming effects of bronchoalveolar macrophages in cerulein-induced pancreatitis rats.
Yamaguchi Y; Matsumura F; Liang J; Okabe K; Matsuda T; Ohshiro H; Ishihara K; Akizuki E; Yamada S; Ogawa M
Pancreas; 1999 May; 18(4):355-63. PubMed ID: 10231840
[TBL] [Abstract][Full Text] [Related]
8. An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan.
Ogata M; Matsumoto T; Koga K; Takenaka I; Kamochi M; Sata T; Yoshida S; Shigematsu A
Infect Immun; 1993 Feb; 61(2):699-704. PubMed ID: 8423096
[TBL] [Abstract][Full Text] [Related]
9. Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1.
Qayumi AK; English JE; Duncan S; Ansley DM; Pearson B; Nikbakht-Sangari M; Sammartino C; Fradet G
J Heart Lung Transplant; 1997 Sep; 16(9):946-55. PubMed ID: 9322146
[TBL] [Abstract][Full Text] [Related]
10. Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart.
Loucks EB; Godin DV; Walley KR; McManus BM; Rahimian R; Granville DJ; Hong JM; Aktary FM; Qayumi AK
Can J Cardiol; 2003 Mar; 19(3):267-74. PubMed ID: 12677282
[TBL] [Abstract][Full Text] [Related]
11. Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock.
Okano S; Tagawa M; Urakawa N
J Vet Med Sci; 1995 Aug; 57(4):751-3. PubMed ID: 8519912
[TBL] [Abstract][Full Text] [Related]
12. Platelet activating factor causes hyperconstriction at the inflammatory coronary lesions in pigs in vivo.
Kozai T; Shimokawa H; Yamawaki T; Fukumoto Y; Kadokami T; Kuwata K; Katsumata N; Egashira K; Takeshita A
Coron Artery Dis; 1997 Jul; 8(7):423-32. PubMed ID: 9383603
[TBL] [Abstract][Full Text] [Related]
13. Effect of platelet-activating factor antagonist on brain injury in rats.
Tokutomi T; Sigemori M; Kikuchi T; Hirohata M
Acta Neurochir Suppl (Wien); 1994; 60():508-10. PubMed ID: 7976632
[TBL] [Abstract][Full Text] [Related]
14. The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia.
Yin M; Buurman WA; Daemen JW; Kootstra G
Transplantation; 1996 May; 61(10):1443-6. PubMed ID: 8633367
[TBL] [Abstract][Full Text] [Related]
15. Effect of the platelet-activating factor antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock.
Yamanaka S; Iwao H; Yukimura T; Kim S; Miura K
Br J Pharmacol; 1993 Dec; 110(4):1501-7. PubMed ID: 8306093
[TBL] [Abstract][Full Text] [Related]
16. Regional haemodynamic effects of platelet activating factor in the rat.
King KA; Lim SL; Pang CC
Eur J Pharmacol; 1995 Aug; 281(2):187-93. PubMed ID: 7589206
[TBL] [Abstract][Full Text] [Related]
17. The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion.
Suzuki S; Serizawa A; Sakaguchi T; Tsuchiya Y; Kojima Y; Okamoto K; Kurachi K; Konno H; Fujise Y; Baba S; Nakamura S
Transplantation; 2000 Jun; 69(11):2267-73. PubMed ID: 10868624
[TBL] [Abstract][Full Text] [Related]
18. Immunoregulatory functions of paf-acether. II. Decrease of CD2 and CD3 antigen expression.
Vivier E; Salem P; Dulioust A; Praseuth D; Metezeau P; Benveniste J; Thomas Y
Eur J Immunol; 1988 Mar; 18(3):425-30. PubMed ID: 2895712
[TBL] [Abstract][Full Text] [Related]
19. Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309.
Takatani M; Maezaki N; Imura Y; Terashita Z; Nishikawa K; Tsushima S
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():943-6. PubMed ID: 1825438
[No Abstract] [Full Text] [Related]
20. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group.
Poeze M; Froon AH; Ramsay G; Buurman WA; Greve JW
Shock; 2000 Oct; 14(4):421-8. PubMed ID: 11049104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
